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A2A adenosine receptor deletion is protective in a mouse model
of Tauopathy
C Laurent1,2,11, S Burnouf1,2,11, B Ferry3,12, VL Batalha4,12, JE Coelho4,12, Y Baqi5,6, E Malik5, E Mariciniak1,2, S Parrot3,7, A Van der Jeugd8,
E Faivre1,2, V Flaten1,2, C Ledent9, R D’Hooge8, N Sergeant1,2,10, M Hamdane1,2,10, S Humez1,2, CE Müller5, LV Lopes4, L Buée1,2,10 and
D Blum1,2,10
Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer’s
disease (AD) in humans and mitigates both amyloid and Tau burden in transgenic mouse models. However, the impact of selective
A2AR blockade on the progressive development of AD-related lesions and associated memory impairments has not been
investigated. In the present study, we removed the gene encoding A2AR from THY-Tau22 mice and analysed the subsequent effects
on both pathological (Tau phosphorylation and aggregation, neuro-inflammation) and functional impairments (spatial learning and
memory, hippocampal plasticity, neurotransmitter profile). We found that deleting A2ARs protect from Tau pathology-induced
deficits in terms of spatial memory and hippocampal long-term depression. These effects were concomitant with a normalization of
the hippocampal glutamate/gamma-amino butyric acid ratio, together with a global reduction in neuro-inflammatory markers and
a decrease in Tau hyperphosphorylation. Additionally, oral therapy using a specific A2AR antagonist (MSX-3) significantly improved
memory and reduced Tau hyperphosphorylation in THY-Tau22 mice. By showing that A2AR genetic or pharmacological blockade
improves the pathological phenotype in a Tau transgenic mouse model, the present data highlight A2A receptors as important
molecular targets to consider against AD and Tauopathies.
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INTRODUCTION
Consumption of the methylxanthine caffeine is beneficial in
age-related cognitive decline.1 More importantly, longitudinal
and retrospective epidemiological studies show that it delays
dementia onset and reduces Alzheimer’s disease (AD) risk.1
Consistent with these epidemiological observations, chronic
treatment with caffeine in AD animal models improves memory
and mitigates accumulation of amyloid peptides and hyperpho-
sphorylated Tau proteins, the two neuropathological hallmarks of
this disorder.2,3
Caffeine is a non-selective adenosine A2A receptor (A2AR)
antagonist.4 A2ARs are constitutively activated G-protein-coupled
receptors, preferentially expressed in striato-pallidal medium spiny
neurons, but are also present, to a lower extent, in cortical and
hippocampal neurons.5 Neuronal A2ARs modulate excitability by
pre-synaptic control of neurotransmitter release, notably gluta-
mate, as well as by post-synaptic control of excitability.6,7 A2ARs are
also expressed by astrocytes and microglia, controlling their
activation state and their ability to uptake glutamate or to release
pro-inflammatory factors.6 Blockade of A2ARs has been shown to
afford neuroprotection in various neurodegenerative conditions,
such as stroke and Parkinson’s disease.8 Interestingly, the
protective effects of caffeine achieved in Parkinson’s disease
models are mimicked by A2AR pharmacological blockade and gene
deletion.9,10 In sharp contrast, the amount of data regarding the
impact of A2AR modulation in AD is still scarce. So far, A2AR
blockade was found to be protective against the acute toxicity of
amyloid peptides.11 However, the impact of A2AR blockade on the
progressive development of AD-related lesions and associated
memory impairments has not been investigated yet. Furthermore,
even if Tau pathology has a pivotal role in AD,12,13 the relationships
between A2ARs and Tau pathology have been totally overlooked.
In the present study, we explored the outcome of A2AR gene
deletion in the THY-Tau22 transgenic mouse model, which progres-
sively develops hippocampal Tau pathology and spatial memory
defects.14,15 Our data demonstrate that A2AR deletion normalizes
memory, hippocampal plasticity and neurotransmitter imbalance, but
also reduces Tau hyperphosphorylation in these transgenic animals.
In addition, oral administration of a selective A2AR antagonist (MSX-3)
improves spatial memory and reduces Tau hyperphosphorylation in
Tau mice. These findings support the concept of A2ARs as valuable
targets against AD progression and pathology.
MATERIALS AND METHODS
Animals
A2AR knockout animals and THY-Tau22 Tau transgenic mice have been
described elsewhere.14,15,16 Parental lines used were both on C57Bl6/J
background. Experimental animals were generated by mating THY-Tau22
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male mice with A2A
+/− female animals. F1 THY-Tau22 A2A
+/− males were
then crossed with A2A
+/− females to generate F2 double-mutant animals,
that is, THY-Tau22 A2A
− /− (referred as Tau A2A
− /−), and related littermate
controls, that is, WT A2A
+/+, WT A2A
− /− and THY-Tau22 A2A
+/+ (referred as
Tau A2A
+/+). Genotyping was realized by PCR analysis of tail DNA as
described.14,16 Mice were housed in a pathogen-free facility, 5 to 6 per
cage (Techniplast cages 1284L; Lyon, France), maintained on a 12-h light/
12-h dark cycle with ad libitum access to food and water. Body
temperature was evaluated before animal sacrifice and showed no
statistical differences between groups (not shown). We did not identify
any differences in the mouse survival rate, regardless of the genotype.
Since no overt gender differences were observed (see for instance
Supplementary Figure 1), data from both males and females were analysed
as a single group. All experiments were performed at 6–7 months of age,
when Tau transgenic mice are known to exhibit significant Tau pathology
and memory alterations.17,18 All protocols were approved by an ethics
committee (no. 342012, CEEA).
Treatment of THY-Tau22 mice with MSX-3
MSX-3 is a water-soluble prodrug of the potent and highly selective A2AR
antagonist MSX-219 that crosses the blood–brain barrier.20 The drug was
given to THY-Tau22 male mice in drinking water at a dose of 0.3 g l− 1.
Chronic delivery at this dose achieved, in 7-month-old C57Bl6/J mice,
plasma and brain concentrations of MSX-2 of about 10–20 nM (not shown),
compatible with A2AR blockade (Ki = ca. 8 nM). At this dose, MSX-3 alone was
devoid of effects on hippocampal-dependent memory in C57Bl6/J mice
(not shown). Animals were randomized according to their body weight into
the following three experimental groups: WT/H2O, THY-Tau22/H2O and Tau/
MSX-3. The MSX-3 solution was kept in bottles protected from light and
changed weekly. Treatment was started at 6 months of age, an age at
which Tau pathology and memory impairments are already significant in
THY-Tau22 mice (see Figures 1 and 2), and was continued until 8.5–
9 months of age. Body weight was measured weekly. MSX-3 consumption
was assessed throughout treatment for each experimental cage, allowing to
Figure 1. Adenosine A2A receptor (A2AR) deletion prevents behavioural impairments in Tau transgenic mice. (a, b) Effect of A2AR deletion on
spatial memory using Y-maze task. (a) During the exposure phase, all groups explored the maze equally, spending a similar amount of time in
each available arm (P40.05, one-way analysis of variance (ANOVA)). (b) During the test phase, the discrimination index, representative of a
spatial preference for the ‘novel’ arm, was significantly set above chance (50%) for WT A2A
+/+ and WT A2A
− /− animals (Po0.05 for WT A2A+/+,
Po0.001 for WT A2A− /− vs 50%; Student’s t-test). While hippocampus-dependent spontaneous spatial novelty preference was impaired in
Tau A2A
+/+ mice (**Po0.01 vs WT A2A+/+, one-way ANOVA), Tau A2A− /− mice exhibited a normalized preference for the ‘novel’ arm (###Po0.001 vs
Tau A2A
+/+, one-way ANOVA), indicating that A2A deletion prevented memory alterations in Tau transgenic mice. N= 7–11 per group. (c–e) Effect
of A2AR deletion on spatial memory using the Morris water maze. (c) Learning was found to be similar for all genotypes, as indicated by the
equivalent path length needed to find the hidden platform (P40.05, two-way ANOVA). (d) All genotypes exhibited a comparable velocity in
the maze, suggesting no motor deficits (P40.05, one-way ANOVA). (e) Spatial memory was assessed 72 h after the last day of learning. Results
represent the percentage of time spent in the target (T) vs non-target (NT) quadrants. Wild-type (WT) animals (both A2A
+/+ and A2A
− /−) spent
significantly more time in the T quadrant, indicative of a preserved spatial memory. While Tau A2A
+/+ mice displayed memory deficits as
underlined by their lack of preference for the T quadrant, Tau A2A
− /− mice behaved as non-transgenic animals, suggesting a rescue of Tau-
related memory impairments by A2AR deletion.
XXXPo0.001, NT vs T (Student’s t-test); **Po0.01, Tau A2A+/+ vs WT A2A+/+, and ##Po0.01, Tau A2A+/+
vs Tau A2A
− /− (one-way ANOVA); N= 19–24 per group. Results are expressed as mean± s.e.m.
Figure 2. Adenosine A2A receptor (A2AR) deletion reduces hippocampal Tau phosphorylation and impacts Tau kinases in THY-Tau22 mice. (a)
Representative two-dimensional profile of total human Tau in Tau A2A
+/+ (top) vs Tau A2A
− /− (bottom) mice, showing a reduced amount of Tau
acidic species in Tau A2A
− /− animals (arrow; Total Tau C-ter antibody). (b) Quantification of Tau phosphorylation on Thr212/Ser214, Ser262,
Thr181, Ser404 and Ser214 epitopes, as well as dephosphorylated Tau (Tau1) in Tau A2A
+/+ and Tau A2A
− /− mice (#Po0.05 vs Tau A2A− /−, N= 6–7 per
group, Student’s t-test). Results are expressed as a percentage of Tau A2A
+/+± s.e.m. (c) Representative western blots of sarkosyl-soluble (S) and
-insoluble (I) hippocampal Tau species of Tau A2A
+/+ (top) and Tau A2A
− /− (bottom) mice, showing no overt difference between the two genotypes
(Total Tau C-ter antibody). T shows the total amounts of Tau in non-fractionated samples. Quantification of insoluble Tau species is
represented in the graph below (N= 5 per group). (d) Quantification of the Tau kinase changes (GSK3β, AMPK, Erk, P38, JNK and cdk5 and its
regulator p35/p25), as well as of the catalytic subunit of its main phosphatase PP2A (#Po0.05 and ##Po0.01 vs Tau A2A− /−, N= 6–7 per group,
Student’s t-test). Results are expressed as a percentage of Tau A2A
+/+± s.e.m.
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estimate the average consumption per mice. Body temperature was
evaluated at completion of the protocol before the Y-maze task.
Behavioural evaluation
Exploratory test. Open-field exploration was examined using a 50
cm×50 cm arena. Each mouse was placed in the arena for 10min.
Movements were recorded using EthoVision video tracking equipment and
software (Noldus Bv, Wageningen, The Netherlands). Total path length was
measured as an index of mouse locomotion.
Rotarod test. Motor coordination and equilibrium were tested on an
accelerating rotarod (MED Associates Inc., St Albans, VT, USA). Mice were
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placed on the rod with their head directed against the direction of the
rotation so that the animal had to progress forward to maintain its balance.
Mice were first trained on a constant speed (4 r.p.m., 2 min) before starting
with four test trials (intertrial interval, 10 min). During these trials, mice had
to balance on the rotating rod that accelerated from 4 to 40 r.p.m. within
5min. The latency until the mice fell from the rotating rod was recorded,
up to a maximum of 5min.
Anxiety test. The elevated plus maze was used to investigate anxiety-
related behaviour. The apparatus consisted of a plus-shaped maze with
two closed and two open arms (5 cm wide). Mice were placed at the centre
of the maze with their face in the direction of a closed arm, and were
allowed to explore freely for 10min. Five infrared beam detectors,
connected to a PC activity logger, recorded the behaviour of the mice.
Percentage of time spent in the open arms was recorded.
Y-maze test. Short-term spatial memory was assessed in a spontaneous
novelty-based spatial preference Y-maze test as described.21 Each arm of
the Y-maze was 22 cm long, 6.4 cm wide, with 15-cm-high opaque walls.
Different extramaze cues were placed on the surrounding walls. Sawdust
was placed in the maze during the experiments and mixed between each
phase. Allocation of arms was counterbalanced within each group. During
the exposure phase, mice were placed at the end of the ‘start’ arm and
were allowed to explore the ‘start’ arm and the ‘other’ arm for 5 min
(beginning from the time the mouse first left the start arm). Access to the
third arm of the maze (‘novel’ arm) was blocked by an opaque door. The
mouse was then removed from the maze and returned to its home cage
for 2 min. In the test phase the mouse was placed again in the ‘start’ arm of
the maze, the door of the ‘novel’ arm was removed and the mouse was
allowed to explore the maze for 1 min (from the time the mouse first left
the start arm). The amount of time the mouse spent in each arm of the
maze was recorded during both exposure and test phases using
EthovisionXT (Noldus Information Technology, Wageningen, The Nether-
lands). For the exposure phase, we calculated the percentage of time spent
in the ‘other’ arm vs the ‘start’ arm. For the test phase, a discrimination
index [novel arm/(novel+other arm)] × 100 was calculated.
Morris water maze. Spatial memory abilities were evaluated in the
standard hidden platform (PF) acquisition and retention version of the
water maze, as we previously described.3 A 100-cm circular pool was filled
with water, opacified with non-toxic white paint (Viewpoint, Lyon, France)
and kept at 21 °C. A 10-cm round PF was hidden 1 cm beneath the surface of
the water at a fixed position. Four positions around the edge of the tank
were arbitrarily designated 1, 2, 3 and 4, thus dividing the tank into four
quadrants (clockwise): target (hidden PF contained), adjacent 1, opposite
and adjacent 2.
During the learning procedure, mice were tested during the light phase
between 08:00 and 18:00 hours. Each mouse was given four swimming trials
per day (20-min intertrial interval) for five consecutive days. The start
position (1, 2, 3 or 4) was pseudo-randomized across trials. A trial consisted
of placing the mouse into the water facing the outer edge of the pool in one
of the virtual quadrants and allowing it to escape to the hidden PF. A trial
terminated when the animal reached the PF, where it was allowed to remain
for 15 s. If the animal failed to find the target before 120 s, it was manually
guided to the PF, where it was allowed to stay for 15 s. After completion of a
trial, mice were removed from the pool and placed back to their home cages
beneath heat lamps in order to reduce the loss of temperature. Time
required to locate the hidden escape PF (escape latency) and distance
travelled to the hidden escape PF (path length) was recorded using the
Ethovision XT tracking system (Noldus, Wageningen, The Netherlands).
Swimming speed (that is, velocity, as a measure of possible motor defects
that could interfere with their ability to perform in this task) was also
measured. Seventy-two hours following the acquisition phase, a probe trial
was conducted. During this probe trial (60 s), the PF was removed and the
search pattern of the mice was tracked again. Proportion of time spent in
the target quadrant vs averaged non-target quadrants was determined.
Biochemical analyses
Mice used for biochemical evaluations and mRNA studies were quickly
killed by decapitation, as anaesthesia promotes Tau hyperphosphory-
lation.22 Brains were removed and hippocampi were dissected out using a
coronal acrylic slicer (Delta Microscopies, Mauressac, France) at 4 °C and
stored at − 80 °C until use.
For all biochemical experiments, tissue was homogenized in 200 μl Tris
buffer (pH 7.4) containing 10% sucrose and protease inhibitors (Complete;
Roche Diagnostics, Meylan, France), sonicated and kept at − 80 °C until
use. Protein amounts were evaluated using the BCA assay (Pierce,
Rockford, IL, USA).
Bi-dimensional electrophoresis experiments were performed as pre-
viously described.23 Briefly, lysates were precipitated with methanol/
chloroform. Fifteen micrograms of proteins were dissolved in 2D buffer
(7 M urea, 2 M thiourea, 4% CHAPS and 0.6% pharmalytes). Lysates were
loaded on immobilized pH gradient strip 3–11 ReadyStrip (Amersham GE,
Velizy-Villacoublay, France) and isoelectrofocused with the Protean IEF cell
(Amersham GE) according to the manufacturer’s instructions. The strips
were layered onto a 4–12% Bis–Tris poly-acrylamide gel. Membranes were
incubated with anti-total Tau antibody (Cter).
For sarkosyl-soluble/insoluble protein preparations, hippocampi were
homogenized by sonication in a lysis buffer containing 10mM Tris-HCl, pH
7.4, 0.32 M sucrose, 800mM NaCl and 1mM EGTA with protease inhibitors
(Complete w/o EDTA, Roche Diagnostics), and centrifuged at 12 000 g
for 10 min at 4 °C.24 The supernatant incubated 1 h in 1% sarkosyl
(N-laurylsarkosine sodium salt, Sigma, Saint-Quentin-Fallavier, France) at
room temperature was then centrifuged at 100 000 g for 1 h at 4 °C, thus
forming the supernatant and pellet containing sarkosyl-soluble and
-insoluble Tau species, respectively. Sarkosyl-insoluble proteins were
directly resuspended in LDS 2× and sarkosyl-soluble samples were mixed
with LDS 2× , supplemented with reducing agents (Invitrogen, Saint Aubin,
France). Sarkosyl-soluble and -insoluble samples were loaded onto NuPage
Novex (Invitrogen) gels at a ratio of 1:2 (v:v).
For western blots, proteins were diluted with LDS 2× supplemented
with reducing agents (Invitrogen) and then separated on NuPage Novex
gels (Invitrogen). Proteins were transferred to nitrocellulose membranes,
which were then blocked (5% non-fat dry milk or 5% bovine serum
albumin in TNT:Tris-HCl 15mM, pH 8, NaCl 140mM, 0.05% Tween) and
incubated with primary and secondary antibodies. Signals were visualized
using chemiluminescence kits (ECLTM, Amersham Velizy-Villacoublay,
Villacoublay, France) and a LAS3000 imaging system (Fujifilm, Tokyo,
Japan). Total proteins were quantified vs glycéraldéhyde-3-phosphate
déshydrogénase. Phosphorylated proteins were quantified vs total
counterpart. Quantifications were performed using ImageJ software. All
primary antibodies used are described in Table 1.
mRNA extraction and quantitative real-time reverse transcription
(RT)-PCR analysis
Total RNA was extracted from hippocampi and purified using the RNeasy
Lipid Tissue Mini Kit (Qiagen, Courtaboeuf, France). One microgram of
total RNA was reverse-transcribed using the Applied Biosystems
(Saint-Aubin, France) High-Capacity cDNA reverse transcription kit.
Quantitative real-time reverse transcriptase-PCR analysis was performed
on an Applied Biosystems Prism 7900 System using Power SYBR Green PCR
Master Mix. The thermal cycler conditions were as follows: hold for 10min
at 95 °C, followed by 45 cycles of a two-step PCR consisting of a 95-°C step
for 15 s followed by a 60-°C step for 25 s. Sequences of the primer used are
given in Table 2. Cyclophilin A was used as internal control. Amplifications
were carried out in triplicate and the relative expression of target genes
was determined by the ΔΔCT method.
ELISA analysis
Hippocampal tissues were homogenized in RIPA buffer (Tris HCl 25mM,
NaCl 150mM, NP40 1%, sodium deoxycholate 1%, SDS 0.1%, pH 7.6). The
resulting lysates were sonicated and incubated for 1 h at 4 °C under
agitation before centrifugation (12 000 g, 4 °C, 15 min). Supernatants were
collected and protein amounts evaluated using the BCA assay (Pierce).
CCL3, CCL4 and CCL5 levels were quantified using commercially available
ELISA assays (R&D Systems, Abingdon, UK) after loading 300 μg of proteins
in 50 μl volume.
Immunohistochemistry
GFAP immunohistochemistry was performed as previously described21
using 40 μm floating brain sections from paraformaldehyde-perfused
brains of the different experimental groups. Quantification of the GFAP
staining intensity was performed using Image J Software (Scion
Image, Bethesda, MD, USA).
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Electrophysiological recordings
Animals were killed by cervical dislocation, decapitated, the brain rapidly
removed and the hippocampi dissected in ice-cold Krebs solution
composed of (mM): NaCl 124; KCl 3; NaH2PO4 1.25; NaHCO3 26; MgSO4
1; CaCl2 2; and glucose 10 (previously gassed with 95% O2 and 5% CO2, pH
7.4). Slices (400 μm thick) were obtained with a McIlwain tissue chopper,
left to recover for at least 1 h in Krebs solution, and field excitatory
postsynaptic potentials were recorded as previously described in the CA1
stratum radiatum.25 Long-term depression protocol (LTD, 3 trains with
10min interval of 2 Hz, 1,200 pulses) was adapted from Van der Jeug
et al.,26 recorded at 32 °C with a constant flow of 3ml min− 1.
Microdialysis and neurotransmitter determinations
For microdialysis studies, mice were anaesthetized with urethane (1.62
g kg− 1, i.p.) and placed in a stereotaxic frame (David Kopf, Tujunga, CA,
USA) with the body temperature maintained close to 37.5 °C using a
heated under-blanket (Harvard Instruments, Les Ulis, France). The skull was
exposed and, after drilling an appropriate hole, a homemade microdialysis
probe was implanted in a randomized manner in the right or left dorsal
hippocampus (coordinates relative to the bregma: AP − 1.8 mm, L
± 1.5 mm, V − 2.4 mm below the brain surface) according to the atlas of
Franklin & Paxinos. Concentric microdialysis probes were constructed from
regenerated cellulose dialysis tubing (MWCO 6000 Da, 225mm o.d., 1 mm
active dialysis length) and fused-silica capillary tubing, the body of the
probe being made of a 3-cm 26-G stainless steel tube. The probes were
perfused at a rate of 1 μl min− 1 with artificial cerebrospinal fluid (149mM
NaCl, 2.80mM KCl, 1.2 mM MgCl2, 1.2 mM CaCl2, 2.78mM phosphate buffer,
pH 7.4). At least 2 h was allowed to elapse after microdialysis probe
implantation before collection of basal samples (fractions 1, 2 and 3).
Samples were collected every 5 min. Samples were stored and kept at
− 80 °C before analyses. At the end of the experiment, the mice were
decapitated; the implanted hemisphere was removed and the placement
of the cannula was verified on the frozen hemisphere.27
To evaluate gamma-amino butyric acid (GABA) and glutamate levels in
dialysates, 5 μl of sample and 5 μl of standard solutions were derivatized at
room temperature by adding 2 μl of a mixture (1:2:1 v/v/v) of (i) internal
standard (10–4mol l− 1 cysteic acid in 0.117mol l− 1 perchloric acid), (ii) a
Table 1. Antibodies used in this study
Name Abbreviation Epitope Type Origin Provider WB
Tau
Anti-phospho-MAPT (pSer214) PS214 pS214 Poly Rabbit Sigma 1/1000
Anti-PHF, clone AT100 AT100 pT212, pS214 Mono Mouse Thermo Scientific 1/1000
Anti-phospho-MAPT (pThr181) AT270 pT181 Mono Mouse Thermo Scientific 1/1000
Anti-phospho-MAPT (pSer404) PS404 pS404 Poly Rabbit Invitrogen 1/10 000
Anti-phospho-MAPT (pSer262) PS262 pS262 Poly Rabbit Invitrogen 1/1000
Anti-Tau-1, clone PC1C6 Tau1 Non-phospho-S195,198, 199, 202 Mono Mouse Millipore 1/2000
Anti-total Tau Cter Cter last 15 aa of COOH terminus Poly Rabbit Home-made 1/2000
Others
CDK5 (C-8) CDK5 CDK5 COOH terminus Poly Rabbit Santa Cruz Biotechnology 1/1000
Phospho-p44/42 MAPK (Erk1/2) P-ERK pT202, pY204 Mono Mouse Cell Signaling Technology 1/1000
p44/42 MAPK (Erk 1/2) (3A7) ERK Mouse Erk 1/2 Mono Mouse Cell Signaling Technology 1/1000
Phospho-GSK-3β (Ser9) P-GSK3β (S9) pS9 Poly Rabbit Cell Signaling Technology 1/1000
Phospho-GSK3 (Tyr279/Tyr216)
clone 5G-2F
P-GSK3β (Y216) pY279/Y216 Mono Mouse Millipore 1/1000
GSK-3α/β (011-A) GSK3 Mouse GSK3β1-420 Mono Mouse Santa Cruz Biotechnology 1/2000
Phospho-AMPKα (Thr172) P-AMPK pT172 Poly Rabbit Cell Signaling Technology 1/1000
AMPKα AMPK Human AMPKα amino-terminal region Poly Rabbit Cell Signaling Technology 1/1000
P35 (C-19) P35 Human P35 COOH terminus Poly Rabbit Santa Cruz Biotechnology 1/1000
Phospho-p38 MAPK (Thr180/Tyr182) P-P38 pT180/pT182 Poly Rabbit Cell Signaling Technology 1/1000
P38 MAPK P38 Human p38 Poly Rabbit Cell Signaling Technology 1/1000
Phospho-JNK (Thr183/Tyr185) P-JNK pT183/pY185 Poly Rabbit Cell Signaling Technology 1/1000
JNK JNK Mouse JNK Poly Rabbit Cell Signaling Technology 1/1000
Anti-PP2A, C subunit, clone 1D6 PP2A C Human PP2A C subunit 295-309 Mono Mouse Millipore 1/2000
Demethylated-PP2A, C clone 4B7 deMe-PP2A Unmethylated C-terminal region Mono Mouse Santa Cruz Biotechnology 1/1000
Phospho-PP2A (Tyr307) P-PP2A pY307 Poly Rabbit Abcam 1/1000
GAPDH GAPDH Human GAPDH FL1-335 Poly Rabbit Santa Cruz Biotechnology 1/10 000
Abbreviations: AMPK, 5' AMP-activated protein kinase; GAPDH, glycéraldéhyde-3-phosphate déshydrogénase; GSK3β, glycogen synthase kinase 3β;
JNK, c-Jun N-terminal kinase; MAPT, microtubule-associated protein tau; Mono, monoclonal; PHF, paired-helical filaments; Poly, polyclonal; WB, dilution used in
western blotting.
Table 2. Primer sequences used in this study
Name Accession number Primer FW (5′–3′) Primer R (5′–3′) Amplicon size
CD68 NM_009853.1 GACCTACATCAGAGCCCGAGT CGCCATGAATGTCCACTG 95
GFAP NM_001131020.1 CGCGAACAGGAAGAGCGCCA GTGGCGGGCCATCTCCTCCT 104
CCL3 NM_011337.2 TGCCCTTGCTGTTCTTCTCT GTGGAATCTTCCGGCTGTAG 112
CCL4 NM_013652.2 GCCCTCTCTCTCCTCTTGCT GAGGGTCAGAGCCCATTG 72
CCL5 NM_013653.3 CTCACTGCAGCCGCCCTCTG CCGAGCCATATGGTGAGGCAGG 51
TNFα NM_013693.2 TGCCTATGTCTCAGCCTCTTC GAGGCCATTTGGGAACTTCT 116
GAT1 NM_178703.4 TGTTGGTTGGACTGGAAAGG ACGGAAGAACAGGATGATAAG 75
GAT2 NM_144512.2 GTGCCCATATCTGAGGTTGC ATCACCACAGCTCGAGGGTA 70
GAT3 NM_172890.3 GAGCAGGGTGTGCCTATTG GTAGGCGATGAAAGCCAGTC 62
hTau NM_016835.4 GTACGGGTTGGGGGACAGGA CCCGGTTCCTCAGATCCGTC 129
Cyclophilin NM_008907.1 AGCATACAGGTCCTGGCATC TTCACCTTCCCAAAGACCAC 126
Abbreviations: FW, forward; R, reverse.
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borate/NaCN solution (100:20 v/v mixture of 500mmol l− 1 borate buffer,
pH 8.7, and 87mmol l− 1 NaCN in water) and (iii) a 2.925-mmol l− 1 solution
of naphthalene-2,3-dicarboxaldehyde in acetonitrile/water (50:50 v/v). The
samples were then analysed for amino-acid content using an automatic
capillary electrophoresis P/ACE™ MDQ system (Beckman, Brea, CA, USA)
equipped with a ZETALIF laser-induced fluorescence detector (Picometrics,
Labege, France). Excitation was performed using a diode laser (Oxxius,
Lannion, France) at a wavelength of 410 nm, the emission wavelength
being 490 nm. Separations were carried out on a 63 cm×50 μm i.d. fused-
silica capillary (Composite Metal Services, Worcester, England) with an
effective length of 52 cm. Each day, before the analyses, the capillary was
sequentially flushed with 0.25mol l− 1 NaOH (15 min), ultra-pure water
(15min) and running buffer (75 mmol l− 1 sodium borate, pH 9.20± 0.02,
containing 10mmol l− 1 HP-β-CD and 70mmol l− 1 SDS) (5 min). The
separation conditions were an applied voltage of 25 kV, hydrodynamic
sample injection (10 s at 0.6 psi) and a temperature between 41 and 43 °C.
The capillary was sequentially flushed for 30 s each with 0.25mol l− 1
NaOH, ultra-pure water and running buffer between analyses. Electro-
pherograms were acquired at 15 Hz using Karat 32 software.28
Statistics
Results are expressed as means± s.e.m. Differences between mean values
were determined using the Student’s t-test, two-way analysis of variance
(ANOVA) or one-way ANOVA, followed by a post-hoc Fisher’s LSD test using
Graphpad Prism Software. P values o0.05 were considered significant.
RESULTS
A2AR deletion prevents behavioural impairments in Tau transgenic
mice
We evaluated the impact of A2AR deletion on behavioural
impairments of THY-Tau22 mice at the age of 7 months. First,
we determined the effects of A2AR deletion on spatial memory
using Y-maze task. During the exposure phase, all groups explored
the maze equally, spending a similar amount of time in the two
available arms (P40.05; Figure 1a). During the test phase, we
found that the discrimination index, reflecting the preference of
mice for the novel arm vs the familiar arm, was significantly above
chance (that is, 450%) for WT A2A
+/+ (P= 0.03) and WT A2A
− /−
(Po0.0001) animals, both groups exhibiting a similar performance
(P= 0.6, one-way ANOVA; Figure 1b). Importantly, while Tau A2A
+/+
mice exhibited an impaired preference for the new arm (P= 0.24
when compared to chance, that is, 50%; P= 0.0023 in Tau A2A
+/+ vs
WT A2A
+/+, one-way ANOVA), the discrimination index of Tau A2A
− /−
animals was found to be significantly higher than that of Tau A2A
+/+
mice (P= 0.0003 in Tau A2A
− /− vs Tau A2A
+/+, one-way ANOVA;
P= 0.0015 when compared to chance, that is, 50%; Figure 1b),
indicative of an improved spatial memory.
In addition, we evaluated the impact of A2AR deletion on the
development of memory impairments of THY-Tau22 mice using
Morris water maze. As shown in Figure 1c, following path length
calculations, there was no significant difference between groups
during the learning phase using two-way ANOVA analysis
(P40.05). Also, neither Tau nor A2A genotypes influenced animal
velocity (P40.05; Figure 1d). Seventy-two hours following
acquisition, a probe trial was performed. Regardless of A2AR
expression, WT animals exhibited a significant preference for the
target quadrant (Figure 1e; WT A2A
+/+: Po0.0001; WT A2A− /−:
Po0.0001 vs non-target quadrants), with a significantly greater
proportion of time spent in the former than expected by chance
(that is, 425%; WT A2A
+/+: 36.1 ± 2.3%, Po0.0001; WT A2A− /−: 35.1 ±
1.9%, Po0.0001). Therefore, in line with the Y-maze evaluation,
A2AR deletion itself did not impact spatial memory in WT animals.
As expected, Tau A2A
+/+ mice exhibited major memory impairments
with no preference for the target quadrant (Figure 1e; P40.05 vs
non-target quadrants; P= 0.17 when compared to chance, that is,
25%), as well as a significant reduction of the percentage of time
spent in the latter as compared to WT animals (WT A2A
+/+:
36.1 ± 2.3% vs Tau A2A
+/+: 29.1 ± 2.9%, P= 0.009; one-way ANOVA).
In sharp contrast, A2AR deletion prevented memory impairments
in THY-Tau22 animals. Indeed, Tau A2A
− /− mice manifested a
significant preference for the target quadrant (Figure 1e,
Po0.0001 vs non-target quadrants) and spent a significantly
greater proportion of their time in the former than expected by
chance (37.6 ± 2.9%, P= 0.0003). Furthermore, one-way ANOVA
analysis indicated that Tau A2A
− /− mice spent a higher percentage
of time in the target quadrant than Tau A2A
+/+ animals (37.6 ± 2.9%
vs 29.1 ± 2.9%; P= 0.002; Figure 1e), while they exhibited a score
similar to WT A2A
+/+ (37.6 ± 2.9% vs 36.1 ± 2.3%; P= 0.6) and WT A2A
− /−
groups (37.6 ± 2.9% vs 35.1 ± 1.9%; P= 0.36). In THY-Tau22 mice,
similar beneficial effects of A2AR deletion were found regardless of
mice gender (Supplementary Figure 1). Altogether, these beha-
vioural evaluations indicated that A2AR deletion prevents spatial
memory alterations in THY-Tau22 mice.
Of note, we also checked motor performances using open-field
and rotarod tasks. We did not find significant differences in path
length and latency to fall between experimental groups
(Supplementary Figures 2A and B). We also analysed the impact
of A2AR deletion on anxiety using the elevated plus maze task.
THY-Tau22 mice spent significantly more time in the open arms as
compared to controls (WT: 28.7 ± 1.6% vs Tau A2A
+/+: 36.7 ± 3.7%;
P= 0.04, one-way ANOVA; Supplementary Figure 2C), whereas
A2AR knockout animals exhibited the opposite phenotype
(WT: 28.7 ± 1.6% vs A2A
− /−: 19.9 ± 2.1%, P= 0.04, one-way ANOVA).
In the THY-Tau22 background, A2AR deletion normalized the
anxiety profile. Tau A2A
− /− mice spent significantly less time in the
open arms than Tau A2A
+/+ animals (Tau A2A
− /−: 28.9 ± 2.8%,
P= 0.04 vs Tau A2A
+/+; one-way ANOVA) and exhibited a similar
score to that of WT animals (P= 0.04 vs WT; P= 0.95, one-way
ANOVA; Supplementary Figure 2C). A2AR deletion thus appears to
normalize anxiety impairments in THY-Tau22 mice.
A2AR deletion reduces hippocampal Tau phosphorylation in THY-
Tau22 mice
Spatio-temporal progression of Tau pathology in the AD brains
correlates with the progression of cognitive symptoms.12,13 Accord-
ingly, progressive development of hippocampal Tau pathology
parallels memory impairments in THY-Tau22 mice.15 Therefore, we
investigated whether the memory improvement seen in Tau A2A
− /−
mice were related to any changes in Tau protein. In a first attempt,
given the important number of phosphorylation sites on Tau (480),29
we performed a two-dimensional (2D) gel electrophoresis analysis to
evaluate global charge changes of human Tau protein in Tau A2A
+/+ vs
Tau A2A
− /− animals. We observed a reduction of Tau isovariants at the
acidic pH range in Tau A2A
− /− mice as compared to Tau A2A
+/+ animals,
suggesting a reduced Tau phosphorylation (arrow; Figure 2a).
A moderate reduction of phosphorylation was observed by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
at the level of several Tau phospho-epitopes. As compared to
Tau A2A
+/+ animals, Thr181 and Ser404 epitopes showed a trend
for reduced phosphorylation in Tau A2A
− /− animals (Thr181:
− 24.9 ± 6.1%, P= 0.09; Ser404: − 27.4 ± 8.8%, P= 0.09 vs Tau A2A
+/+,
Student’s t-test) and phosphorylation on Ser214 was found to be
significantly reduced (−32.9 ± 5.1% of Tau A2A
+/+, P= 0.04, Student’s
t-test; Figure 2b and Supplementary Figure 3a). Conversely,
phosphorylation on Thr212/Ser214 (AT100) and Ser262 epitopes
as well as Tau1 staining, reflecting dephosphorylated Tau at
Ser195/198/199/202, remained unchanged in Tau A2A
− /− vs Tau A2A
+/+
animals (P= 0.26, P= 0.35 and P= 0.56, respectively, Student’s
t-test; Figure 2b and Supplementary Figure 3a). Noteworthy, A2AR
deletion did not influence transgene expression as human Tau
mRNA levels remained unchanged in Tau A2A
− /− vs Tau A2A
+/+ animals
(not shown). Tau protein levels and proteolytic fragments, known
to favour aggregation,30 were also unaffected in both groups (not
shown), suggesting that A2AR deletion does not affect the stability
or the degradation of human Tau proteins. Finally, to study the
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impact of the A2AR knockout on Tau aggregation, biochemical
fractionation was performed and sarkosyl-soluble/insoluble frac-
tions analysed. The amount of sarkosyl-insoluble Tau remained
similar in Tau A2A
+/+ and Tau A2A
− /− mice (P40.05; Figure 2c).
A2AR deletion and kinase/phosphatase balance in THY-Tau22 mice
Tau phosphorylation is under the tight control of a kinase/
phosphatase balance. More than 30 different kinases are able to
phosphorylate Tau.29 We thus evaluated the impact of A2AR
deletion on activation of major Tau kinases, namely GSK3β, AMPK,
p42/44 MAPK (Erk), p38 MAPK, JNK and Cdk5. As shown in
Figure 2d and Supplementary Figure 3b, we observed that in THY-
Tau22 mice A2AR deletion led to a significant increase of GSK3β
phosphorylation at the Ser9 inactivating epitope (+40.8 ± 10.0% of
Tau A2A
+/+ mice; P= 0.009, Student’s t-test), as well as to a mild but
significant reduction of Cdk5 immunoreactivity (−18.4 ± 2.9% of
Tau A2A
+/+ mice; P= 0.04, Student’s t-test) without any change in the
level of its pathological activator p25. Conversely, phosphorylation
of AMPK, Erk, p38 and JNK remained unchanged in Tau A2A
− /− mice.
In addition, we addressed expression, demethylation and Y307
phosphorylation of the catalytic subunit of PP2A (PP2Ac), the main
Tau phosphatase. Results showed that PP2Ac remained unaffected
by A2AR knockout in THY-Tau22 animals (Figure 2d and Supple-
mentary Figure 3b). The reduced Tau phosphorylation seen in Tau
A2A
− /− mice thus appears to be likely associated to changes in
GSK3β and cdk5 kinases.
A2AR deletion modulates hippocampal neuro-inflammation in
THY-Tau22 mice
Tau transgenic models have been previously shown to exhibit
hippocampal neuro-inflammation, progressing along the develop-
ment of hippocampal Tau pathology and behavioural altera-
tions.3,31 Of interest, neuro-inflammation favours Tau hyperphos-
phorylation32 and memory dysfunctions33 and A2AR blockade has
been suggested to mitigate neuroinflammatory processes.6,34
These observations prompted us to investigate the effects of A2AR
deletion on the neuro-inflammatory markers previously found to
be upregulated in Tau transgenic mice.3 As expected, we found
that mRNA expression of microglial (CD68) and astroglial (GFAP)
markers as well as of several pro-inflammatory cytokines (CCl3,
CCl4, CCl5 and TNFα) were significantly upregulated in the
hippocampus of Tau A2A
+/+ animals, with most of them significantly
reduced in Tau A2A
− /− mice (CD68: − 18.8 ± 6.9%, P= 0.03; GFAP:
− 38.1 ± 4.6%, P= 0.0004; TNFα: − 34.3 ± 7.5%, P= 0.0004; CCl3:
− 33.0 ± 11.5%, P= 0.02; and CCl5: − 29.3 ± 10.1%, P= 0.02 vs Tau
A2A
+/+, one-way ANOVA; Supplementary Figure 4B). Using immu-
nohistochemistry and ELISA, we confirmed that A2AR deletion
normalized GFAP expression and CCl3 levels in Tau mice
(Supplementary Figures 4B and C). In WT animals, A2AR deletion
itself had no significant effect on the levels of all markers studied.
A2AR deletion modulates hippocampal levels of glutamate and
GABA
A2ARs regulate neuronal pre-synaptic release as well as astrocyte-
based reuptake of glutamate and GABA.6,35,36 THY-Tau22 mice
exhibit higher hippocampal glutamate levels compared to WT
animals, regardless of the A2AR genotype (P= 0.021; two-way
ANOVA; Figure 3a). Surprisingly, hippocampal GABA levels were
found to be significantly upregulated in the hippocampus of Tau
A2A
− /− animals, reaching 206± 16% of Tau A2A
+/+ (P= 0.003 using one-
way ANOVA; Figure 3b). Subsequently, glutamate/GABA ratio
was found to be increased in Tau A2A
+/+ as compared to WT animals
(WT A2A
+/+: 7.3 ± 1.2 vs Tau A2A
+/+:13.9 ± 2.8, P= 0.05, one-way ANOVA)
while normalized to control levels in Tau A2A
− /− mice (8.4 ± 2.6,
P= 0.75 vs WT A2A
+/+). Hippocampal mRNA levels for the GABA
transporters (GATs) 1, 2 and 3 were significantly increased in Tau
A2A
+/+ mice, whereas both GAT-2 and GAT-3 expression returned to
control levels in Tau A2A
− /− animals (Supplementary Figure 5).
A2AR deletion rescues LTD deficits in THY-Tau22 transgenic mice
We previously demonstrated that impaired hippocampal-
dependent learning and memory in THY-Tau22 transgenic mice
was associated with attenuated long-term depression.26 Slices
from WT animals developed a robust and similar LTD regardless of
A2AR expression (WT A2A
− /− vs WT A2A
+/+, P40.05; two-way ANOVA;
Figure 4a). As expected, Tau A2A
+/+ mice exhibited an impaired
LTD maintenance as compared to WT A2A
+/+ animals (Po0.001 vs
WT A2A
+/+, two-way ANOVA; Figure 4a and b), with a significant
reduction, reaching 31.6 ± 3.5% of controls (P= 0.008 vs WT A2A
+/+,
one-way ANOVA; Figure 4b). In contrast, LTD remained unaffected
in Tau A2A
− /− mice (Po0.001 vs Tau A2A+/+, two-way ANOVA;
Figure 4a), being similar to WT animals (P= 0.82, Figure 4b).
Beneficial effects of A2AR-based therapy using the selective
antagonist MSX-3 in Tau transgenic mice
We explored the effect of MSX-3, a water-soluble prodrug of
MSX-2, which is a potent and highly selective A2AR antagonist.
19
THY-Tau22 mice received MSX-3 through drinking water (0.3 g l− 1)
starting at 6 until 8.5–9 months of age. At completion of the
Figure 3. Adenosine A2A receptor (A2AR) deletion modulates
hippocampal levels of glutamate and gamma-amino butyric acid
(GABA). Glutamate (a) and GABA (b) concentrations in microdialy-
sates recorded from the dorsal hippocampus of anaesthetized mice.
The histograms represent the mean± s.e.m. of three consecutive 5-
min microdialysates following a 2-h post-implantation equilibration
period (*Po0.05 using two-way analysis of variance (ANOVA);
##Po0.01 in Tau A2A− /− vs Tau A2A+/+, N= 6–9 per group, one-way
ANOVA).
Figure 4. Adenosine A2A receptor (A2AR) deletion rescues long-term
depression (LTD) deficits in THY-Tau22 transgenic mice. (a) Plots of
the field excitatory postsynaptic potential (fEPSP) slope variation
over time after induction of LTD in hippocampal slices. While Tau A2A
+/
+ mice displayed an impaired LTD as compared to WT (A2A
+/+ or A2A
− /−)
animals, slices from Tau A2A
− /− animals exhibited LTD similar to
control animals, suggesting that A2A deletion rescues LTD in Tau
mice. (b) Quantification of the percentage of variation of the fEPSP
slope during the LTD maintenance phase, 60 min after induction
(**Po0.01 in Tau A2A+/+ vs WT A2A+/+; ##Po0.01 in Tau A2A− /− vs Tau A2A+/+;
N= 4–7 per group, one-way analysis of variance).
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experiment, body weight gain was not different between water-
and MSX3-treated Tau animals (Tau/H2O: 120.1 ± 1.4% of their
initial body weight; Tau/MSX-3: 122.9 ± 1.1% of their initial body
weight; P= 0.13 vs water consumers). Body temperature was also
similar in all experimental groups (not shown). Mice consumed on
average 4.7 ± 0.3 ml of the MSX-3 solution every day, correspond-
ing to an average daily intake of 1.4 mg of the antagonist.
Spatial memory was evaluated using the Y-maze task. During
the exposure phase, all groups spent a similar amount of time in


















































Figure 5. The specific A2A receptor antagonist MSX-3 improves spatial memory and reduces Tau hyperphosphorylation in THY-Tau22 mice.
MSX-3 treatment started at 6 months, an age at which Tau pathology and memory impairments are already significant (see Figures 1 and 2)
until 8.5–9months. (a–c) Effect of MSX-3 on the spatial memory of THY-Tau22 mice using Y-maze task. During the exposure phase (a), all
groups explored the maze equally, spending a similar amount of time in each available arm (P40.05, one-way analysis of variance (ANOVA)).
All genotypes exhibited a comparable velocity in the maze (b; P40.05, one-way ANOVA). During the test phase (c), while hippocampus-
dependent spontaneous spatial novelty preference was impaired in Tau/H2O mice (*Po0.05 vs WT, one-way ANOVA), Tau mice treated with
MSX-3 exhibited a normalized preference for the ‘novel’ arm (#Po0.001 vs Tau/H2O, one-way ANOVA; N= 9–15 per group). (d) Representative
two-dimensional profile of total human Tau protein in Tau/H2O (top) vs Tau/MSX-3 (bottom) mice, showing a reduced amount of Tau acidic
species in Tau animals treated with the adenosine A2A receptor antagonist (arrow; Total Tau C-ter antibody). (e) Tau phosphorylation on
Thr212/Ser214, Ser262, Thr181, Ser404 and Ser214 epitopes, as well as dephosphorylated Tau (Tau1) in Tau/H2O and Tau/MSX-3 mice
(*Po0.05 and **Po0.01 vs Tau, N= 6–8 per group, Student’s t-test). Results are expressed as a percentage of Tau/H2O ± s.e.m. (f)
Representative western blots of sarkosyl-soluble (S) and -insoluble (I) hippocampal Tau species of Tau/H2O (top) and Tau/MSX-3 (bottom) mice,
showing no overt difference between the two groups (Total Tau C-ter antibody).
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the discrimination index was significantly impaired in Tau mice
treated with water (P= 0.0022 in Tau/H2O vs WT/H2O, one-way
ANOVA; Figure 5c). Tau/MSX-3 animals exhibited an index higher
than that of Tau/H2O mice (P= 0.05 in Tau/MSX-3 vs Tau/H2O, one-
way ANOVA; Figure 5c) and similar to control animals (Tau/MSX-3
vs WT/H2O, one-way ANOVA; P= 0.36), indicative of an improved
spatial memory.
We then investigated whether these memory improvements
were related to changes of Tau protein. Using two-dimensional
(2D) gel electrophoresis analysis, we observed a reduction of Tau
isovariants at the acidic pH range in Tau/MSX-3 mice as compared
to Tau/H2O animals, suggesting a reduced Tau phosphorylation
(arrow; Figure 5d). Accordingly, we observed a reduction of Tau
phosphorylation at several Tau phospho-epitopes using sodium
dodecyl sulphate-polyacrylamide gel electrophoresis. As com-
pared to Tau/H2O animals, we found a significantly reduced
phosphorylation at Ser262, Ser404 and Ser214 epitopes in Tau/
MSX-3 vs Tau/H2O animals (Figure 5e). Phosphorylation at Thr212/
Ser214 (AT100) and Thr181 epitopes as well as Tau1 staining
remained unchanged. MSX-3 treatment did not affect total Tau
protein levels (Figure 5e) nor Tau proteolytic fragments
(not shown). Finally, the MSX-3 effect on Tau aggregation was
evaluated using biochemical fractionation. The amount of
sarkosyl-insoluble Tau remained similar in Tau/H2O and Tau/
MSX-3 animals (Figure 5f).
DISCUSSION
The present study provides the first evidence that A2AR deletion is
sufficient to prevent memory defects, hippocampal plasticity
impairments as well as Tau hyperphosphorylation, in a mouse
model of AD. Accordingly, our data also demonstrate that
treatment with a specific A2AR antagonist, starting from a
symptomatic stage, improves spatial memory and reduces Tau
hyperphosphorylation in THY-Tau22 mice.
The role of A2ARs in AD is ill-defined. Previous studies demon-
strated a significant A2AR upsurge in the brain of AD patients, visible
at early Braak stages.37 Consistent with the view that such A2AR
dysfunction is detrimental towards hippocampal function,25 epide-
miological and experimental studies have shown that the con-
sumption of caffeine, a non-selective A2AR antagonist, reduces AD
risk and mitigates AD lesions.1,2,3 However, the specific relationship
between A2ARs and AD has been overlooked. While recent findings
suggested that genetic and pharmacological A2AR blockade
mitigates acute Aβ synaptotoxicity in mice,11 the impact of A2AR
modulation on the pathophysiological progression of AD hallmarks,
including specific lesions, remained totally unknown so far.
In the present study, we demonstrate that A2AR deletion
significantly prevents the development of spatial memory deficits
in THY-Tau22 transgenic mice, using Y-maze and Morris water
maze tasks. A2AR deletion itself does not lead to any learning and
memory changes in WT animals. This is consistent with previous
studies showing that, unlike working memory, global or forebrain-
specific A2AR deletion spares spatial reference memory in
mice.38,39 Overall, our results are in agreement with previous data
showing that A2A receptor blockade is pro-cognitive in various
conditions leading to memory decline, such as ageing,40 chronic
stress,25 β-amyloid acute toxicity11 or traumatic brain injury.41
Importantly, MSX-3 treatment rescued hippocampal-dependent
memory in Tau mice even after onset of the pathology. This
supports the idea that A2A receptor blockade is efficient not only
to prevent but also to revert deficits in our model of AD-like Tau
pathology. Accordingly, pharmacological A2A receptor blockade
was shown to revert memory deficits in a chronic stress model
induced by maternal separation.25
Tau hyperphosphorylation has been associated to cognitive
impairments in several dementing disorders29 as well as in various
experimental models.17,42 Obviously, Tau-related memory
impairments are dissociated from Tau aggregation.3,24,43 Our
present results demonstrate that A2AR deletion or blockade by
MSX-3 promotes a moderate but significant reduction of Tau
hyperphosphorylation as notably seen using 2D electrophoresis.
This occurs while Tau aggregation remains unchanged, as
supported by unmodified AT100 immunoreactivity and sarkosyl-
insoluble Tau. This suggests that the observed memory improve-
ments following A2AR deletion or pharmacological blockade are
likely related, at least in part, to changes in Tau phosphorylation
status. Interestingly, the effects of A2AR deletion on Tau pathology
are distinct from those observed following chronic caffeine intake
in the same mouse model.3 Indeed, Tau epitopes found changed
in the present study (essentially pSer214) are different from those
found modulated by caffeine (AT100, Tau1). Moreover, in contrast
to caffeine, A2AR deletion does not influence the amount of Tau
proteolytic fragments.3 Taken together, these data support that
regulation of Tau by caffeine is likely resulting from a broader
range of action than only inhibition of A2AR activity.
Tau phosphorylation is under the control of phosphatases,
essentially PP2A, and a number of distinct kinases (430).29 Here,
we found that the deletion of A2AR did not affect the expression,
methylation and phosphorylation of PP2A in Tau mice. Rather, our
data show that A2AR deletion increases the levels of pSer9 GSK3β
phosphorylation, which inversely correlates with its activity, as
well as slightly reduces Cdk5 expression in Tau transgenic mice.
Notably, these two kinases target Tau epitopes that were modified
by A2AR deletion in THY-Tau22 mice.
29
We cannot rule out that glial-based phenomena underlie some of
the beneficial effects resulting from A2AR blockade. It is known that
activation of microglia and pro-inflammatory cytokines promotes
Tau hyperphosphorylation32,44 through kinase activation.45 A2ARs
are expressed by astroglial and microglial cells, modulating both
their activation as well as their ability to release pro-inflammatory
factors or to reuptake glutamate.6,35,46 According to this, A2A
receptor blockade has been shown to reduce neuro-inflammation
in different pathological situations.34,47,48 While further studies
would be needed to identify the precise underlying mechanisms,
our data suggest that A2AR deletion contributes to the reported
changes of Tau hyperphosphorylation presumably through a
reduction of hippocampal neuroinflammation in THY-Tau22 trans-
genic mice. Additionally, astrocytes play a key role in regulating
adenosine homeostasis and hippocampal plasticity.49,50 Adenosine
metabolic clearance is highly regulated by adenosine kinase, a
phosphotransferase predominantly expressed by the astrocytes of
the adult brain.51 Interestingly, astrocytic adenosine kinase upsurge
following astrogliosis has been associated with cognitive impair-
ments including hippocampal-dependent memory.52,53 The fact
that A2ARs play a role in astrocyte activation
6 and that Tau A2A
− /−
mice exhibit reduced astrogliosis further supports the hypothesis
of an astrocyte contribution to the A2AR-mediated THY-Tau22
deficits.
In addition to pathological markers, we evaluated the impact of
A2AR deletion on neurochemical and synaptic hippocampal
indexes. A2ARs have been shown to modulate neurotransmitter
dynamics by regulating both synaptic release and glial
uptake.6,35,36 Regardless of A2AR genotype, we found that THY-
Tau22 mice exhibited a limited but significant increase in
hippocampal glutamate levels. These observations are in accor-
dance with the somewhat increased vulnerability of these Tau
mice when challenged with pentylenetetrazol—a GABAA receptor
antagonist—as well as the abnormal synaptic response of THY-
Tau22 slices to bicucullin, another GABAA receptor antagonist
(unpublished data). A2ARs regulate presynaptic glutamate release
as well as glutamate re-uptake by astrocytes.6,35 Also, A2A receptor
blockade in astrocytes is able to counteract β-amyloid toxicity by
increasing glutamate uptake.54 However, we could not observe
any changes in glutamate levels following A2A receptor deletion.
Rather, we observed that A2AR deletion led to a significant
A2A receptor targeting in Tau mice
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increase in hippocampal GABA levels in Tau mice. While the
differential impact of A2AR deletion on GABA levels in WT and Tau
mice remains puzzling, these observations are in line with data
reporting regulation of neuronal and glial GABA uptake by A2A
Rs.36,55 Accordingly, we observed a significant decrease of GAT-2
and GAT-3 expression levels in the hippocampus of Tau A2A
− /− vs
Tau A2A
+/+ animals. Overall, changes in GABA levels resulted in a
normalization of the glutamate/GABA ratio. Previous studies
suggested that normalization of the latter could be associated
to neuroprotection as well as to memory improvements in various
neuropathological models.56–58
Finally, behavioural improvements observed in Tau A2A
− /− animals
were found to be associated with a rescue of hippocampal long-
term depression (LTD). As we previously reported in older mice,
behavioural deficits seen in THY-Tau22 mice are associated with an
impaired LTD,26 in the absence of neuronal death and synaptic
shrinkage.17 The combined observation of LTD normalization and
memory improvement in Tau A2A
− /− mice argues for an instrumental
role of LTD defect towards cognitive dysfunction in this mouse
model. This is in accordance with previous reports linking
hippocampal LTD to memory abilities.59,60 Interestingly, similarly
to what has been observed using a specific antagonist,61 A2AR
knockout itself did not impact LTD, in our experimental conditions,
in line with the preserved spatial memory of WT A2A
− /− animals. The
mechanisms underlying LTD normalization in Tau A2A
− /− mice
remain to be determined. Despite moderate changes, reduced Tau
hyperphosphorylation and neuro-inflammation might contribute
to the rescue of LTD deficit.62 Another explanation may rely on
GSK3β activity changes. A recent systematic evaluation of the role
of kinases in hippocampal LTD revealed that among 58 kinases
investigated only GSK3β inhibition was associated with LTD
impairments.63 At first sight, these data are at odds with our
observations. However, we demonstrated that, conversely to WT
animals, GSK3β inhibition leads to LTD normalization in slices from
THY-Tau22 mice (Ahmed et al.64). Reduced GSK3β activation,
besides impacting Tau phosphorylation, could then play a direct
role towards the synaptic improvement seen in Tau A2A
− /− animals.
Finally, the ability of BDNF to impair LTD has recently been
demonstrated.61 The BDNF upsurge described in the hippocampus
of THY-Tau22 mice14 could thus play a role in the LTD impairments
seen in this strain. Interestingly, BDNF’s effects on LTD were found
to be dependent on A2AR activation.
61 It remains thus possible that
A2AR deletion in THY-Tau22 mice could gate these BDNF-
dependent effects, resulting in LTD normalization. This will deserve
further studies.
In conclusion, we have shown for the first time that both A2AR
gene deletion and pharmacological blockade are effective in a
model of AD-like Tau pathology. Therefore, the present findings
highlight A2AR targeting as a promising therapeutic strategy in AD
and Tauopathies.
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